Home › Wilms Tumor › New York
Wilms Tumor clinical trials in New York
6 studies for Wilms Tumor are looking for participants at sites in New York.
Cities in New York
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- New York Medical College, Valhalla
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- and 9 more
RecruitingPhase 2
Up to age 30 · All sexes · Updated Aug 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- and 1 more
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.